Africa: Six in Seven Covid-19 Infections Go Undetected in Africa

14 October 2021

A new assessment by the World Health Organization (WHO) shows that only 14.2% - or one in seven - COVID-19 infections are being detected in Africa. To reverse that trend and curb transmission, the WHO Regional Office for Africa today announced a new initiative to enhance community screening for COVID-19 in eight countries. The programme aims to reach more than 7 million people with rapid diagnostic tests in the next year.

The WHO analysis used the COVID-19 calculator developed by Resolve to Save Lives which estimates infections based on reported number of cases and deaths and an infection fatality rate grounded in population-based studies. It found that as of 10 October 2021 the cumulative number of COVID-19 infections is estimated to be 59 million in Africa, which is seven times more than the over 8 million cases reported.

To date, COVID-19 detection in Africa has focused on people reporting to health facilities with symptoms, in addition to testing arriving and departing international travellers, leading to large-scale under-reporting given the high percentage of asymptomatic cases on the continent.

Since the start of the pandemic and as of 10 October, more than 70 million COVID-19 tests have been reported by African countries, which is a fraction of the continent's 1.3 billion people. By contrast, the United States, with about a third of the population, has reportedly administered over 550 million tests, while the United Kingdom, with less than 10% of the population of Africa, has administered over 280 million tests.

"With limited testing, we're still flying blind in far too many communities in Africa. Most tests are carried out on people with symptoms, but much of the transmission is driven by asymptomatic people, so what we see could just be the tip of the iceberg. Test numbers have been rising in Africa, but this community-based initiative is a radically new approach which should help significantly raise detection rates. More testing means rapid isolation, less transmission and more lives saved through targeted action," said Dr Matshidiso Moeti, WHO Regional Director for Africa."

The countries participating in the programme are Burundi, Cote d'Ivoire, Democratic Republic of the Congo, Guinea-Bissau, Mozambique, Republic of the Congo, Senegal and Zambia. To kick off implementation, WHO has disbursed US$ 1.8 million to the eight countries. WHO will support countries to interrupt disease transmission, through active case finding by deploying teams in local communities to seek out possible contacts of people who have tested positive for COVID-19 and offer antigen rapid diagnostic tests.

The initiative will use a "ring strategy", which was pioneered successfully in the eradication of smallpox in the latter half of the 20th century to vaccinate people who are most likely to be infected, and during the recent Ebola outbreaks in West Africa and in the Democratic Republic of the Congo. The ring approach will target people living inside a circle of 100 metres radius around each new confirmed case to prevent further spread of the disease.

In addition, each household within the 100 metres radius will receive hygiene kits including face masks and hand sanitizers and anyone who tests positive will be assessed for the severity of their condition to determine whether they should receive home-based care or need to be transferred to designated COVID-19 treatment centres.

Related Stories:

As new Ebola outbreak emerges in the DRC...14 Oct, 2021

Children must be protected amidst civil ...14 Oct, 2021

UN Committee on Migrant Workers issues f...14 Oct, 2021

The programme aims to increase the testing capacity in each participating country by 40%, ensuring they reach the WHO recommended benchmark of 10 tests performed per 10 000 people weekly. Currently, around 20 countries - more than a third of African countries - do not reach this benchmark

All testing will be carried out on a voluntary basis and will be conducted using WHO-approved antigen based rapid diagnostic tests, which can produce results on-site in as little as 15 minutes and can be administered with minimal training. Rapid diagnostic tests are considered highly accurate for detecting infections that have reached the transmissible stage. Currently, most countries carry out polymerase chain reaction or PCR tests, which require reagents and experts, and are significantly more time-consuming and expensive than rapid diagnostic tests.

There have now been over 8.4 million COVID-19 cases recorded in Africa, including 214 000 deaths. Despite a decline in case numbers in recent weeks, vaccination rates remain low, with only 30% of the continent's 54 nations having fully vaccinated 10% of their population against the disease-compared with almost 90% of high-income countries. Meanwhile, just under half of the African countries that have received COVID-19 vaccines have fully vaccinated just 2% or less of their populations.

In the absence of enough vaccines, a more proactive community testing effort is especially important for reducing transmission in African countries where a relatively youthful population is contributing to a high rate of asymptomatic infections. Estimates show that between 65% and 85% of COVID-19 infections in Africa generate few or no symptoms. As a result, most Africans infected with the disease do not seek out treatment in local health facilities where most testing now occurs. Yet, asymptomatic individuals are playing a key role in facilitating transmission to vulnerable individuals who can suffer severe disease or death.

"Public health authorities in Africa have so far been rightly focused on managing the cases coming into treatment centres and hospitals," Dr Moeti said. "But now is the time to go on the offensive against COVID-19, and work with local communities to break transmission chains and stop wider outbreaks from happening."

Dr Moeti spoke during a virtual press conference today facilitated by APO Group. She was joined by Dr Aly Ngon Tambdou, Deputy Chief Medical Officer, Dakar Health Region, Senegal, and Dr Ngozi Erondu Senior Scholar, O'Neill Institute, Georgetown University and Associate Fellow, Chatham House Global Health Programme.

Also on hand to respond to questions were Dr Richard Mihigo, Coordinator, Immunization and Vaccines Development Programme, WHO Regional Office for Africa, Dr Fiona Braka, Team Lead, Emergency Operations, WHO Regional Office for Africa and Dr Thierno Balde, Regional COVID-19 Deputy Incident Manager, WHO Regional Office for Africa.

Distributed by APO Group on behalf of WHO Regional Office for Africa.

AllAfrica publishes around 700 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.

X